Download PDF
J Neurol Surg B Skull Base 2020; 81(06): 610-619
DOI: 10.1055/s-0039-1693659
Original Article

Loss of SMARCB1 Expression Confers Poor Prognosis to Sinonasal Undifferentiated Carcinoma

Chandala Chitguppi
1   Department of Otolaryngology and Head and Neck Surgery, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, United States
,
Mindy R. Rabinowitz
1   Department of Otolaryngology and Head and Neck Surgery, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, United States
,
Jennifer Johnson
2   Department of Hematology and Medical Oncology, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, United States
,
Voichita Bar-Ad
3   Department of Radiation Oncology–Head and Neck Cancer, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, United States
,
Judd H. Fastenberg
1   Department of Otolaryngology and Head and Neck Surgery, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, United States
,
Jeremy Molligan
4   Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, United States
,
Ethan Berman
1   Department of Otolaryngology and Head and Neck Surgery, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, United States
,
Gurston G. Nyquist
1   Department of Otolaryngology and Head and Neck Surgery, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, United States
,
Marc R. Rosen
1   Department of Otolaryngology and Head and Neck Surgery, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, United States
,
James E. Evans
5   Department of Neurological Surgery, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, United States
,
Stacey K. Mardekian
4   Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, United States
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Background Due to the diverse histopathologic features and variable survival rates seen in sinonasal undifferentiated carcinoma (SNUC), it is likely that this diagnostic entity is comprised of a heterogonous group of morphologically undifferentiated tumors. As advancements in molecular testing have led to a better understanding of tumor biology, it has become increasingly evident that SNUC may actually encompass several tumor subtypes with different clinical behavior. As a result, it is also likely that all SNUC patients cannot be treated in the same fashion. Recent investigations have identified loss of the tumor suppressor SMARCB1 (INI1) expression in a subset of undifferentiated sinonasal tumors and extrasinonasal tumors and, studies have suggested that this genetic aberration may be a poor prognostic marker. The objective of this study was to identify differential expression of SMARCB1 in SNUC and to analyze and compare the survival outcomes in SNUC patients with and without SMARCB1 expression.

Methods All cases of undifferentiated or poorly differentiated neoplasms of the sinonasal tract treated between 2007 and 2018 at a single tertiary care institution were selected. All cases of SNUC were tested for SMARCB1 status by immunohistochemistry (IHC). Clinical parameters were analyzed using Student's t-test and Fischer's test. Kaplan–Meier methods were used to estimate survival durations, while comparison between both the subgroups was done using the log-rank test. Statistical analysis was performed with the use of SPSS software, Version 25 (IBM, New York, NY, United States).

Results Fourteen cases of SNUC were identified. Approximately two-thirds (64%; n = 9) of patients were male and the majority (79%; n = 11) were between fifth to seventh decade. Skull base and orbital invasion were seen in 79% (n = 11) and 93% (n = 13) of cases, respectively. Fifty-seven percent of tumors (n = 8) retained SMARCB1 expression by IHC (SR-SNUC), while the remaining 43% (n = 6) showed loss of SMARCB1 expression and, thus, were considered as SMARCB1-deficient (SD-SNUC). Although clinicopathological features and treatment modalities were similar, SD-SNUC showed poorer (OS: p = 0.07; disease free survival [DFS]: p = 0.02) overall survival (OS) and DFS on Kaplan–Meier curves. Additionally, SD-SNUC showed higher recurrence (75 vs. 17%) and mortality (67 vs. 14%) (hazard rate = 8.562; p = 0.05) rates. Both OS (28.82 ± 31.15 vs. 53.24 ± 37.50) and DFS durations (10.62 ± 10.26 vs. 43.79 ± 40.97) were consistently worse for SD-SNUC. Five-year survival probabilities were lower for SD-SNUC (0.33 vs. 0.85).

Conclusion SNUC represents a heterogeneous group of undifferentiated sinonasal malignancies. Based on the status of SMARCB1 expression, the two subgroups SD-SNUC and SR-SNUC appear to represent distinct clinical entities, with loss of SMARCB1 expression conferring an overall worse prognosis.

Keywords

SMARCB1 - INI-1 - undifferentiated - sinonasal - survival - cancer

Financial Disclosure

None.




Publication History

Received: 05 February 2019

Accepted: 03 June 2019

Article published online:
24 July 2019

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Frierson HF. Sinonasal undifferentiated carcinoma. In: Barnes L, Eveson JW, Reichart P, Sidransky D. ed. World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumors. Zurich, Switzerland: Lyon: IARC Press; 2005: 19
    Google Scholar
  • 2 Rischin D, Porceddu S, Peters L, Martin J, Corry J, Weih L. Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma. Head Neck 2004; 26 (05) 435-441
    CrossrefPubMedGoogle Scholar
  • 3 Ejaz A, Wenig BM. Sinonasal undifferentiated carcinoma: clinical and pathologic features and a discussion on classification, cellular differentiation, and differential diagnosis. Adv Anat Pathol 2005; 12 (03) 134-143
    CrossrefPubMedGoogle Scholar
  • 4 Frierson Jr HF, Mills SE, Fechner RE, Taxy JB, Levine PA. Sinonasal undifferentiated carcinoma. An aggressive neoplasm derived from schneiderian epithelium and distinct from olfactory neuroblastoma. Am J Surg Pathol 1986; 10 (11) 771-779
    CrossrefPubMedGoogle Scholar
  • 5 Righi PD, Francis F, Aron BS, Weitzner S, Wilson KM, Gluckman J. Sinonasal undifferentiated carcinoma: a 10-year experience. Am J Otolaryngol 1996; 17 (03) 167-171
    CrossrefPubMedGoogle Scholar
  • 6 Cerilli LA, Holst VA, Brandwein MS, Stoler MH, Mills SE. Sinonasal undifferentiated carcinoma: immunohistochemical profile and lack of EBV association. Am J Surg Pathol 2001; 25 (02) 156-163
    CrossrefPubMedGoogle Scholar
  • 7 Musy PY, Reibel JF, Levine PA. Sinonasal undifferentiated carcinoma: the search for a better outcome. Laryngoscope 2002; 112 (8, Pt. 1): 1450-1455
    CrossrefPubMedGoogle Scholar
  • 8 Kramer D, Durham JS, Sheehan F. et al. Sinonasal undifferentiated carcinoma: case series and systemic review of the literature. J Otolaryngol 2004; 33 (01) 32-36
    CrossrefPubMedGoogle Scholar
  • 9 Kim BS, Vongtama R, Juillard G. Sinonasal undifferentiated carcinoma: case series and literature review. Am J Otolaryngol 2004; 25 (03) 162-166
    CrossrefPubMedGoogle Scholar
  • 10 Lin EM, Sparano A, Spalding A. et al. Sinonasal undifferentiated carcinoma: a 13-year experience at a single institution. Skull Base 2010; 20 (02) 61-67
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Xu CC, Dziegielewski PT, McGaw WT, Seikaly H. Sinonasal undifferentiated carcinoma (SNUC): the Alberta experience and literature review. J Otolaryngol Head Neck Surg 2013; 42: 2
    CrossrefPubMedGoogle Scholar
  • 12 Khan MN, Konuthula N, Parasher A. et al. Treatment modalities in sinonasal undifferentiated carcinoma: an analysis from the national cancer database. Int Forum Allergy Rhinol 2017; 7 (02) 205-210
    CrossrefPubMedGoogle Scholar
  • 13 Betz BL, Strobeck MW, Reisman DN, Knudsen ES, Weissman BE. Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. Oncogene 2002; 21 (34) 5193-5203
    CrossrefPubMedGoogle Scholar
  • 14 Folpe AL, Schoolmeester JK, McCluggage WG. et al. SMARCB1-deficient Vulvar Neoplasms: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 14 Cases. Am J Surg Pathol 2015; 39 (06) 836-849
    CrossrefPubMedGoogle Scholar
  • 15 Lopez-Beltran A, Cheng L, Raspollini MR, Montironi R. SMARCB1/INI1 Genetic Alterations in Renal Medullary Carcinomas. Eur Urol 2016; 69 (06) 1062-1064
    CrossrefPubMedGoogle Scholar
  • 16 Dabek B, Kram A, Kubrak J. et al. A rare mutation in a rare tumor--SMARCB1-deficient malignant glomus tumor. Genes Chromosomes Cancer 2016; 55 (01) 107-109
    CrossrefPubMedGoogle Scholar
  • 17 Johann PD, Hovestadt V, Thomas C. et al. Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome. Brain Pathol 2017; 27 (04) 411-418
    CrossrefPubMedGoogle Scholar
  • 18 Kohashi K, Oda Y. Oncogenic roles of SMARCB1/INI1 and its deficient tumors. Cancer Sci 2017; 108 (04) 547-552
    CrossrefPubMedGoogle Scholar
  • 19 Laco J, Chmelařová M, Vošmiková H. et al. SMARCB1/INI1-deficient sinonasal carcinoma shows methylation of RASSF1 gene: A clinicopathological, immunohistochemical and molecular genetic study of a recently described entity. Pathol Res Pract 2017; 213 (02) 133-142
    CrossrefPubMedGoogle Scholar
  • 20 Dogan S, Chute DJ, Xu B. et al. Frequent IDH2 R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas. J Pathol 2017; 242 (04) 400-408
    CrossrefPubMedGoogle Scholar
  • 21 Agaimy A, Hartmann A, Antonescu CR. et al. SMARCB1 (INI-1)-deficient sinonasal carcinoma: a series of 39 cases expanding the morphologic and clinicopathologic spectrum of a recently described entity. Am J Surg Pathol 2017; 41 (04) 458-471
    CrossrefPubMedGoogle Scholar
  • 22 Strehl JD, Wachter DL, Fiedler J. et al. Pattern of SMARCB1 (INI1) and SMARCA4 (BRG1) in poorly differentiated endometrioid adenocarcinoma of the uterus: analysis of a series with emphasis on a novel SMARCA4-deficient dedifferentiated rhabdoid variant. Ann Diagn Pathol 2015; 19 (04) 198-202
    CrossrefPubMedGoogle Scholar
  • 23 Snyder P, Lawson S. Evaluating results using corrected and uncorrected effect size estimates. Journal of Experimental Evaluation 1993; 61 (04) 334-349
    PubMedGoogle Scholar
  • 24 Green JL, Camilli G, Elmore PB, Skukauskaiti A, Grace E. (eds.). Research synthesis: effect sizes. Handbook of Complementary Methods in Educational Research. Mahwah, NJ: Erlbaum; 2006: 583-603
    Google Scholar
  • 25 Sullivan GM, Feinn R. Using effect size-or why the p value is not enough. J Grad Med Educ 2012; 4 (03) 279-282
    CrossrefPubMedGoogle Scholar
  • 26 Morand GB, Anderegg N, Vital D. et al. Outcome by treatment modality in sinonasal undifferentiated carcinoma (SNUC): A case-series, systematic review and meta-analysis. Oral Oncol 2017; 75: 28-34
    CrossrefPubMedGoogle Scholar
  • 27 Jeng YM, Sung MT, Fang CL. et al. Sinonasal undifferentiated carcinoma and nasopharyngeal-type undifferentiated carcinoma: two clinically, biologically, and histopathologically distinct entities. Am J Surg Pathol 2002; 26 (03) 371-376
    CrossrefPubMedGoogle Scholar
  • 28 Roberts CWM, Orkin SH. The SWI/SNF complex--chromatin and cancer. Nat Rev Cancer 2004; 4 (02) 133-142
    CrossrefPubMedGoogle Scholar
  • 29 Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011; 11 (07) 481-492
    CrossrefPubMedGoogle Scholar
  • 30 Masliah-Planchon J, Bièche I, Guinebretière JM, Bourdeaut F, Delattre O. SWI/SNF chromatin remodeling and human malignancies. Annu Rev Pathol 2015; 10: 145-171
    CrossrefPubMedGoogle Scholar
  • 31 Agaimy A, Rau TT, Hartmann A, Stoehr R. SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review. Am J Surg Pathol 2014; 38 (07) 910-920
    CrossrefPubMedGoogle Scholar
  • 32 Agaimy A. The expanding family of SMARCB1(INI1)-deficient neoplasia: implications of phenotypic, biological, and molecular heterogeneity. Adv Anat Pathol 2014; a 21 (06) 394-410
    CrossrefPubMedGoogle Scholar
  • 33 Bishop JA, Antonescu CR, Westra WH. SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract. Am J Surg Pathol 2014; 38 (09) 1282-1289
    CrossrefPubMedGoogle Scholar
  • 34 Bell D, Hanna EY, Agaimy A, Weissferdt A. Reappraisal of sinonasal undifferentiated carcinoma: SMARCB1 (INI1)-deficient sinonasal carcinoma: a single-institution experience. Virchows Arch 2015; 467 (06) 649-656
    CrossrefPubMedGoogle Scholar
  • 35 Kalimuthu SN, Chetty R. Gene of the month: SMARCB1. J Clin Pathol 2016; 69 (06) 484-489
    CrossrefPubMedGoogle Scholar